Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

CAMP4 Therapeutics (CAMP) has filed proposed terms to raise $75 million from the sale of its common stock in an IPO, according to an amended SEC registration statement. The firm is a clinical ...

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene ...

On Tuesday, Piper Sandler began coverage of CAMP4 Therapeutics Corp (NASDAQ:CAMP) stock with an Overweight rating and a price target of $18.00. The firm highlighted CAMP4's innovative work in the ...

CAMP4 Therapeutics Corporation CAMP IPO will take place October, 11 on the NASDAQ exchange under the ticker CAMP. The company is offering shares at an expected price between $14.00 and $16.00 per ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Century Therapeutics (IPSC – Research ...

In addition, CAMP4 has granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares of common stock at the initial public offering price, less underwriting discounts ...

On Tuesday, JPMorgan (NYSE:JPM) initiated coverage on NASDAQ:CAMP stock, CAMP4 Therapeutics Corp, with an Overweight rating and a price target of $23.00. The firm's analysis is based on the potential ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings. Individual or entity Most recent transaction Date Shares owned as of transaction date 5AM PARTNERS VI, LLC ...